BL-B16D1

BL-B16D1 is an investigational antibody-drug conjugate (ADC) that targets both the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3/ERBB3). It is designed as a dual-antibody ADC, meaning it simultaneously binds to EGFR and HER3 on tumor cells, delivering a cytotoxic payload via a new generation of toxins. The drug is being developed for the treatment of advanced solid tumors, including unresectable locally advanced or metastatic breast cancer, head and neck cancer, squamous cell carcinoma, and other solid tumors. Its mechanism of action involves inhibiting EGFR and ERBB3 signaling pathways while delivering targeted cytotoxicity through its conjugated toxin.